Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22089696 | 1.00 | CYP2D6 (0.47) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| SCHEMBL22090243 | 1.00 | CYP2D6 (0.47) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| SCHEMBL715065 | 0.89 | CYP2D6 (0.47) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| SCHEMBL31504465 | 0.89 | ALDH1A1 (0.50) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| Isopropylamine SCHEMBL2350740 | 0.87 | CYP2D6 (0.53) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| SCHEMBL1274859 | 0.85 | CYP2D6 (0.51) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| SCHEMBL8976348 | 0.83 | CYP2D6 (0.46) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| Isopropylamine SCHEMBL3156276 | 0.83 | CYP2D6 (0.50) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| Acetonitrile SCHEMBL29256909 | 0.83 | ALDH1A1 (0.52) | CYP2D6MAPK1SNCAALDH1A1MAPT | |
| Acetonitrile SCHEMBL17474635 | 0.83 | ALDH1A1 (0.52) | CYP2D6MAPK1SNCAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-119118999-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118955477-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118903141-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118903142-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-12098142-B2 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-09-24 | — | — | US | disclosed |
| CN-113227074-B | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118388457-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118290403-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11981663-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-05-14 | — | — | US | disclosed |
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230416235-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-12-28 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220298144-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-3877381-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-113227074-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods | 凌科药业(杭州)有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020119819-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CYP2D6 1004/4885MAPK1 964/4885SNCA 2730/4885 |
| US-20220298144-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CYP2D6 1004/4885MAPK1 964/4885SNCA 2730/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | CYP2D6 823/4885MAPK1 179/4885SNCA 1763/4885 |
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CYP2D6 1004/4885MAPK1 964/4885SNCA 2730/4885 |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CYP2D6 1105/4885MAPK1 957/4885SNCA 2600/4885 |
| US-12098142-B2 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | CYP2D6 1037/4885MAPK1 854/4885SNCA 3069/4885 |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CYP2D6 1004/4885MAPK1 964/4885SNCA 2730/4885 |
| US-20230416235-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CYP2D6 1004/4885MAPK1 964/4885SNCA 2730/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | CYP2D6 1105/4885MAPK1 957/4885SNCA 2600/4885 |
| US-11981663-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CYP2D6 1105/4885MAPK1 957/4885SNCA 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.